Targeted Therapies for Migraine Prevention in the Challenging Migraineur: Focus on CGRP Blockade

Targeted Therapies for Migraine Prevention in the Challenging Migraineur: Focus on CGRP Blockade (February 2020)

Sunday, February 16, 2020 in San Diego, CA
Lunch -- Marriott Marquis San Diego Hotel Marina, 12:45 PM PT
Grand Ballroom 8-9


12:45 pm – 1:00 pm Registration and Lunch

1:00  pm – 1:05 pm Opening Remarks

1:05  pm – 1:15 pm Frequent Episodic and Chronic Migraine Overview

1:15  pm – 1:25 pm Update on Migraine Pathophysiology and Therapeutic Targets

1:25  pm – 1:40 pm CGRP Blocker Formulations

1:40  pm – 1:50 pm Putting It All Together

1:50  pm – 2:00 pm Closing Discussion and Question and Answer Session


Wade Cooper, DO

Director, Headache and Neuropathic Pain
Clinical Associate Professor, Neurology and Anesthesiology
University of Michigan
Ann Arbor, Michigan

Merle Diamond, MD

Clinical Assistant Professor
Department of Medicine
Rosalind Franklin University
President, Managing Director
Diamond Headache Clinic
AMITA Health St Joseph Hospital
Chicago, Illinois

Goal Statement
The goal of this activity is to improve participants’ knowledge of and competence in applying current and emerging CGRP-based treatment strategies in migraine prevention and treatment.

Target Audience 
This program is intended for neurologists, headache specialists, primary care physicians, nurses, and other healthcare providers who treat migraine.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify the challenges and unmet needs for safe and effective reduction of migraine burden in patients with frequent episodic or chronic migraine who cannot tolerate or respond poorly to conventional therapies
  • Describe recent investigations into the role of CGRP in the migraine cascade and the rationale for utilizing CGRP blockade for migraine prophylaxis
  • Compare and contrast available and emerging CGRP blockers with respect to administration features, dosing intervals, and pivotal clinical trial results
  • Consider patients’ expectations, preferences, and unmet needs when selecting a CGRP blocker product for migraine prophylaxis


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.